International Clinical Neuroscience Journal

Vol. 10 No. 1 (2023)

Autoimmune Parkinsonism: A Newer Manifestation of Contactin-Associated Protein-Like 2 Autoimmunity: A Case Report

International Clinical Neuroscience Journal, Vol. 10 No. 1 (2023), 15 January 2023 , Page e15

Abstract

Contactin-associated protein-like 2 (CASPR2) antibodies are part of an expanding spectrum of disorders. Although they were initially associated with Morvan’s syndrome and peripheral nerve hyperexcitability, their clinical manifestations are more varied than previously recognized. In this report, we present a rare case of a middle-aged woman who experienced gait disturbances, sleep disturbances, behavioral changes, and postural abnormalities over a period of five months. A thorough examination revealed a Parkinsonian phenotype. Considering the timeline and symptomatology, an autoimmune work-up was conducted, which detected CASPR2 antibodies in the patient’s serum. Treatment with high-dose intravenous Methylprednisolone followed by rituximab effectively reversed her clinical manifestations without residual neurological deficits.

Keywords:
  • Voltage-gated potassium channel antibodies
  • Rituximab therapy
  • High-dose Methylprednisolone
  • Autoimmune Parkinsonism
  • CASPR2 Antibodies
  • Contactin-associated Protein-like 2

How to Cite

1.
Maturu MVS, Datla AV, Devabhaktuni RB, Maturu P, Mandwe DS. Autoimmune Parkinsonism: A Newer Manifestation of Contactin-Associated Protein-Like 2 Autoimmunity: A Case Report. Int Clin Neurosci J [Internet]. 2023 Dec. 20 [cited 2025 May 21];10(1):e15. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/43272

References

Baizabal-Carvallo JF, Jankovic J. Autoimmune and paraneoplastic movement disorders: an update. J Neurol Sci. 2018;385:175-84. doi: 10.1016/j.jns.2017.12.035.

van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87(5):521-8. doi: 10.1212/wnl.0000000000002917.

Poliak S, Gollan L, Martinez R, Custer A, Einheber S, Salzer JL, et al. Caspr2, a new member of the neurexin superfamily, is localized at the juxtaparanodes of myelinated axons and associates with K + channels. Neuron. 1999;24(4):1037-47. doi: 10.1016/s0896-6273(00)81049-1.

Kannoth S, Nambiar V, Gopinath S, Anandakuttan A, Mathai A, Rajan PK. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia. Neurol Sci. 2018;39(3):455-60. doi: 10.1007/ s10072-017-3222-0.

Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology. 2008;70(20):1883-90. doi: 10.1212/01. wnl.0000312275.04260.a0.

Saint M, Alakbarzade V, McLean B. Frontotemporal dementia with parkinsonism and epilepsy associated with VGKC antibodies: case report and literature review. Case Rep Neurol. 2021;13(1):205-10. doi: 10.1159/000513852.

Newsom-Davis J, Buckley C, Clover L, Hart I, Maddison P, Tüzüm E, et al. Autoimmune disorders of neuronal potassium channels. Ann N Y Acad Sci. 2003;998(1):202-10. doi: 10.1196/annals.1254.022.

Rodenas-Cuadrado P, Ho J, Vernes SC. Shining a light on CNTNAP2: complex functions to complex disorders. Eur J Hum Genet. 2014;22(2):171-8. doi: 10.1038/ejhg.2013.100.

Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi: 10.3389/fphar.2013.00177.

Haug BA, Schoenle PW, Karch BJ, Bardosi A, Holzgraefe M. Morvan’s fibrillary chorea. A case with possible manganese poisoning. Clin Neurol Neurosurg. 1989;91(1):53-9. doi: 10.1016/s0303-8467(89)80008-3.

Li Y, Ren H, Ren M, Cui F, Yang F, Chen Z, et al. Morvan syndrome plus thyroid dysfunction: a case with chronic mercury exposure. Neurol India. 2014;62(2):218-9. doi: 10.4103/0028-3886.132439.

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-601. doi: 10.1002/ mds.26424.

Nawfal O, Agha M, Makki A, Beydoun A. Refractory Morvan syndrome responsive to rituximab: a case report and review of the literature. Neuromuscul Disord. 2022;32(8):682-6. doi: 10.1016/j.nmd.2022.06.001.

Wu L, Cai F, Zhuo Z, Wu D, Zhang T, Yang H, et al. CASPR2 antibody associated neurological syndromes in children. Sci Rep. 2023;13(1):2073. doi: 10.1038/s41598-023-28268-x.

Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A, et al. Rituximab treatment and long-term outcome of patients with autoimmune encephalitis: real-world evidence from the GENERATE registry. Neurol Neuroimmunol Neuroinflamm. 2021;8(6):e1088. doi: 10.1212/nxi.0000000000001088.

  • Abstract Viewed: 327 times
  • PDF Downloaded: 248 times

Download Statastics